$ACCV

Jewell Brent C purchased $45K of ACCV

Jewell Brent C (Chief Operating Officer) purchased 2,500 shares of Accelevation Holdings Corp. (ACCV) at $18.00 on 2026-10-01.

Original reporting
SEC EDGAR · Jewell Brent C
Published Oct 6, 2026, 1:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ACCV
Neutral
high confidence
Mentioned
$ACCV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACCVNeutralLow
01

Why it matters

The filing provides primary‑source confirmation of insider confidence, but the monetary amount is modest.

02

Market read

Minor insider purchase; limited immediate market impact.

03

What to watch

If ACCV is in a high‑growth niche, any insider buying could signal confidence.

Relevance 4/10Novelty 3/10Timing: after-hours filing

Background

SEC Form 4 filing discloses an insider purchase by the company's COO.

Company-level read

Ticker impact

$ACCVNeutralHigh confidence
Context

COO Jewell Brent C bought 2,500 shares at $18 each, total $45,000, increasing his stake to 304,068 shares.

Expected impact

potential modest upward pressure as market absorbs insider buying

Evidence & confidence

The transaction size is modest relative to market cap, but insider buying can be viewed positively by traders.

Market effects

None significant; the purchase is company‑specific.

No broader regional effect.

Limited to ACCV shareholders.

Counterpoint

The purchase is too small to move the stock; traders may ignore it.

Key entities

  • Accelevation Holdings Corp.

    Issuer of the Form 4 filing.

  • Jewell Brent C

    Chief Operating Officer of ACCV.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Accelevation's SkyBridge bookings strengthen Bank of America's bullish outlook

Bank of America initiated coverage of Accelevation with a 'buy' rating and $20 price target, citing strong demand for data center equipment. The bank expects adjusted EBITDA to grow at a 56% CAGR from 2026 to 2030, driven by AI infrastructure investments. Accelevation's SkyBridge platform secured $700M in bookings, and the company benefits from a domestic manufacturing footprint and skilled labor.

$ACCVHigh

JPMorgan initiates Accelevation stock with overweight rating

JPMorgan initiated coverage on Accelevation Holdings (NASDAQ:ACCV) with an overweight rating and a $20.00 price target for December 2027, implying 60% upside. The stock trades at $12.38, near its 52-week low. The company reported $726.6M revenue, 29.3% gross margin, and a 1.93 current ratio. JPMorgan cited a $1.1B backlog and modular scaling capabilities as strengths, while noting risks like hyperscaler capex timing and customer concentration.

Med

Accelevation Secures $650 Million Credit Agreement Led By Bank Of America, JPMorgan, Morgan Stanley, KeyBank And PNC

Accelevation Holdings secured a $650 million credit agreement, including a $400 million revolving facility and a $250 million Term Loan A, both maturing in 2031. The new financing reduces borrowing rates and strengthens the company's balance sheet, according to the company. Bank of America, JPMorgan, Morgan Stanley, KeyBank, and PNC were involved in the agreement.